A carregar...
Midostaurin: a novel therapeutic agent for patients with FLT3-mutated acute myeloid leukemia and systemic mastocytosis
The development of FLT3-targeted inhibitors represents an important paradigm shift in the management of patients with highly aggressive fms-like tyrosine kinase 3-mutated (FLT3-mut) acute myeloid leukemia (AML). Midostaurin is an orally administered type III tyrosine kinase inhibitor which in additi...
Na minha lista:
| Publicado no: | Ther Adv Hematol |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
SAGE Publications
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5639976/ https://ncbi.nlm.nih.gov/pubmed/29051803 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2040620717721459 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|